Phase 1/2Data readout

EIK1003 (Selective PARP1 Inhibitor)

Metastatic Prostate Cancer

EIKNEikon Therapeutics

Expected catalystOctober 23, 2026Company guidance: Oct 23, 2026

Catalyst overview

Event details

Drug or asset: EIK1003 (Selective PARP1 Inhibitor)
Development stage: Phase 1/2
Event type: Data readout
Indication: Metastatic Prostate Cancer

Research summary

What is being tracked?

This catalyst tracks a Phase 1/2 data readout for EIK1003 (Selective PARP1 Inhibitor) in Metastatic Prostate Cancer. The expected timing is based on the latest available company guidance and may change.

Development notes

07/20/26:- ESMO 2026 to present initial Phase 1/2 EIK1003 plus abiraterone data in metastatic prostate cancer. 08/13/26:- Initial Cohort 1B EIK1003 plus abiraterone and prednisone data will be presented October 23, 2026.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

EIK1003 (Selective PARP1 Inhibitor)

Event details

What is being tracked?

Development notes

Primary source

Related pipeline programs

EIK1001

EIK1001

EIK1005

EIK1003